Is slowing of movement a side effect of Acuphase (generic name)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Slowing of Movement as a Side Effect of Acuphase

Yes, slowing of movement (bradykinesia) is a recognized side effect of Acuphase (zuclopenthixol acetate), as it can cause extrapyramidal symptoms including movement disorders. 1

Extrapyramidal Side Effects of Acuphase

Acuphase (zuclopenthixol acetate) is an injectable antipsychotic medication that can cause various movement-related side effects:

  • Extrapyramidal symptoms (EPS) are common side effects of Acuphase, which include slowing of movement (bradykinesia), muscle rigidity, and tremor 1
  • These movement disorders occur due to the medication's effects on dopamine receptors in the basal ganglia, which regulate movement control 2
  • The slowing of movement can manifest as reduced spontaneous movements, difficulty initiating movement, and overall slowness in performing motor tasks 3

Types of Movement Disorders Associated with Acuphase

Acuphase can cause several distinct movement-related side effects:

  • Bradykinesia (slowing of movement): Characterized by reduced speed of voluntary movements and difficulty initiating movement 3
  • Dystonia: Involuntary muscle contractions that can cause abnormal postures or movements, including severe cases like laryngeal dystonia 1
  • Akathisia: An inner sense of restlessness and inability to remain still, often manifesting as constant movement or pacing 2, 4
  • Parkinsonism: A syndrome resembling Parkinson's disease with bradykinesia, rigidity, and tremor 3

Risk Factors and Management

Several factors can increase the risk of developing movement disorders with Acuphase:

  • Concurrent use of medications that inhibit cytochrome P450 enzymes (like fluoxetine) can increase zuclopenthixol levels and worsen side effects 1
  • Higher doses of Acuphase are associated with greater risk of extrapyramidal symptoms 1
  • Management options for movement-related side effects include:
    • Dose reduction of Acuphase when possible 2
    • Administration of anticholinergic medications for acute dystonic reactions 2
    • Benzodiazepines may help manage akathisia 2
    • Beta-blockers can be effective for certain extrapyramidal symptoms 2

Clinical Monitoring

Careful monitoring is essential when administering Acuphase:

  • Patients should be observed for signs of slowing movements, rigidity, tremor, or restlessness 1, 2
  • Early recognition of extrapyramidal symptoms is crucial to prevent progression to more severe manifestations 2
  • Monitoring should continue throughout the duration of action of Acuphase, which can last for 2-3 days 1

Important Considerations

  • Movement disorders from Acuphase can range from mild to severe and potentially life-threatening (as in the case of laryngeal dystonia) 1
  • Differential diagnosis between various movement disorders (akathisia, tardive dyskinesia, dystonia) is important for appropriate management 4
  • Some movement disorders may persist even after discontinuation of the medication 4

In clinical practice, the benefits of Acuphase in managing acute psychosis must be carefully weighed against the risk of movement disorders, including bradykinesia, especially in patients with pre-existing movement disorders or those taking medications that may interact with Acuphase 1, 2.

References

Research

Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2010

Research

[Akathisia].

Fortschritte der Neurologie-Psychiatrie, 1997

Research

Distinguishing akathisia and tardive dyskinesia: a review of the literature.

Journal of clinical psychopharmacology, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.